Saad Z. Usmani, MD, MBA, FACP, Details the Safety Profile for CARTITUDE-1 Trial
Usmani discussed the common adverse events observed from CARTITUDE-1, including hematologic events and cytokine release syndrome.
CancerNetwork® sat down with Saad Z. Usmani, MD, MBA, FACP, of the Levine Cancer Institute in Charlotte, North Carolina, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, to discuss the safety profile of the phase 1b/2 CARTITUDE-1 trial that looked at patients with relapsed/refractory multiple myeloma treated with ciltacabtagene autoleucel (cilta-cel).
Transcription:
For CARTITUDE-1, there were no new safety updates because the more common adverse events that we observe with CAR T-cell therapies—not just with the previously reported [B-cell maturation antigen]–directed CAR T-cells, but also with CD19 CAR T-cells—[are] hematologic AEs. Those were quite common and consistent with what has been reported in the past. The same is true for [cytokine release syndrome (CRS)]. Ninety-two patients out of the 97 had CRS, but most of those were grade 1 or grade 2, and CRS resolved in 99% of the patients within 14 days of onset.
Reference
Usmani SZ, Berdeja JG, Madduri D, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1. J Clin Oncol. 2021,39(suppl 15):8005. doi:10.1200/JCO.2021.39.15_suppl.8005
Frontline Chemo-Free Regimen Supported in HR+/HER2+ Breast Cancer Therapy
January 1st 2024Combining anastrozole with palbociclib, trastuzumab, and pertuzumab as a frontline therapy for hormone receptor–positive, HER2-positive breast cancer may avoid some of the toxicities associated with chemotherapy, says Amy Tiersten, MD.
